CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.

Britt I DrögemöllerGalen E B WrightJoanne ShihJose G MonzonKaren A GelmonColin J D RossUrsula AmstutzBruce C Carletonnull null

Published in: Breast cancer research and treatment (2018)

Critical appraisal of the literature provided evidence for the value of comprehensive CYP2D6 genotyping panels in guiding treatment decisions for non-metastatic ER-positive breast cancer patients. Based on this information, it is recommended that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers.

Keyphrases

metastatic breast cancer
end stage renal disease
small cell lung cancer
estrogen receptor
systematic review
squamous cell carcinoma
ejection fraction
chronic kidney disease
newly diagnosed
gene expression
endoplasmic reticulum
peritoneal dialysis
replacement therapy